SCHEMBL10313544

SCHEMBL10313544

Cc1ccc(-c2c(C)nn3c2N=C(c2ccc(F)cc2F)C3=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.41
AR P10275 2/20 0.38
PGR P06401 1/20 0.38
NR3C2 P08235 1/20 0.38
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 1/20 0.34
PTGS2 P35354 2/20 0.33
KDM4E B2RXH2 1/20 0.33
KCNH2 Q12809 1/20 0.33
SRC P12931 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275453 0.89 OPRM1 (0.38) OPRM1PGRNR3C2HPGDSMN1; SMN2
SCHEMBL10275321 0.82 OPRM1 (0.39) OPRM1PGRNR3C2MEN1KMT2A
SCHEMBL10313545 0.81 PGR (0.42) OPRM1ARPGRNR3C2MEN1
SCHEMBL10275360 0.80 AR (0.40) OPRM1ARPGRNR3C2MEN1
SCHEMBL10276440 0.80 OPRM1 (0.38) OPRM1PGRNR3C2HPGDSMN1; SMN2
SCHEMBL10275478 0.79 AR (0.39) OPRM1ARPGRNR3C2KCNH2
SCHEMBL10313507 0.77 PGR (0.40) OPRM1ARPGRNR3C2MEN1
SCHEMBL10276172 0.76 HEXA (0.36) HPGDCYP1A2CYP2D6PTGS2KDM4E
SCHEMBL10313517 0.75 MAT2A (0.38) SMN1; SMN2NPC1LMNARAB9A
SCHEMBL10313529 0.74 CNR1 (0.37) LMNACYP2D6PTGS2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 OPRM1 346/4885AR 3221/4885PGR 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.